Emtricitabine + Tenofovir Disoproxil Fumarate Fixed-Dose Combination as Oral Pre-Exposure Prophylaxis (PrEP) to Reduce the Risk of Sexually Acquired HIV-Infection
Date of publication: December 17, 2021 Decision of the Secretary of Health: Approved (18 January 2022) Evidence Summary: Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection Advisory for Appeals on Preliminary Recommendation: https://bit.ly/PrelimES-OralPrEP-Dec21 HTAC Recommendation Review:
Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Document link: Preliminary Recommendation on Pertuzumab for HER2+ breast cancer (Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.) Document Preview:
Pertuzumab for HER2+ Breast Cancer
Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Document link: Pertuzumab for HER2+ Breast Cancer (Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.) Document Preview:
Sambong 250mg Tablet for Anti-Urolithiasis (Kidney Stones)
SOH approves the HTAC recommendation on the minor inclusion of sambong 250mg tablet in PNF The Secretary of Health approved the HTAC recommendation on the minor inclusion of sambong 250mg tablet for anti-urolithiasis (kidney stones) in the Philippine National Formulary (PNF) on 14 January 2022. Minor inclusions are applicable to drugs that are currently listed in the continue reading : Sambong 250mg Tablet for Anti-Urolithiasis (Kidney Stones)